Dollar-cost averaging with options can be very risky. My option ranges from 1 month to 1 year You can see there are both gains and losses, there's no such thing as a get-rich-quick scheme. $Reddit(RDDT)$  @TigerPM  @Daily_Discussion  @TigerObserver  @Tiger_comments  

In a major breakthrough announced in Geneva, the United States and China have agreed to a 90-day ceasefire in their ongoing trade dispute, accompanied by significant mutual tariff reductions. This move is aimed at easing economic tensions and allowing time for both sides to resolve deeper disagreements. According to the joint statement, the U.S. will reduce its average tariff rate on most Chinese imports — currently totaling 145%, including levies related to fentanyl — to 30% by May 14. In return, China will lower its tariffs on American goods from 125% to 10%. U.S. Treasury Secretary Bessent called the talks "very in-depth and productive," particularly in regard to future fentanyl controls. “Both sides agree that decoupling would be harmful,” she added. Markets Respond Strongly U.S. stock

$Hims & Hers Health Inc.(HIMS)$  Huge beat this quarter! EPS came in at $0.20 vs $0.12 expected, and revenue hit $586M (vs $538.6M est). The company now expects full-year revenue of $2.3–$2.4B and adjusted EBITDA of $295M–$335M. Long-term vision? $6.5B revenue and $1.3B EBITDA by 2030. Bullish: Subscriber base jumped 38% YoY to nearly 2.4 million! Bearish: Switching users from name-brand semaglutide to alternatives might cause short-term revenue dips @TigerPM  @Daily_Discussion  @TigerObserver  @TigerStars  

I'm investigating the possibility of a short squeeze in HIMS$Hims & Hers Health Inc.(HIMS)$  this Monday. To gauge if momentum is building, I can use platforms like Ortex.com, which offers a proprietary estimate of live short interest, though it’s not exact. Alternatively, I must rely on the New York Stock Exchange’s bi-weekly short interest reports, delayed by 10-15 days. For instance, data from April 15th indicated 60 million shares shorted—33% of HIMS’ float—but by April 30th, it was already outdated. For real-time signals, I’d track borrow fees on sites like Fintel or IBorrowDesk, which indicate shorting demand. Rising fees point to heavy shorting pressure, while a drop may suggest covering. Fail-to-deliver d

Microsoft's stellar earnings delivered a Viagra-like push to AI stock enthusiasm, with its share price erected 7% after hours to $422.68 from a previous close of $394.04! The company reported $70.1 billion in revenue, up 13% year-over-year, and an EPS of $3.46, exceeding expectations. Azure’s cloud services excelled, growing 33%—surpassing the 29% forecast—with AI contributing 16% of that growth. Microsoft’s AI integration, fueled by its OpenAI partnership, into products like Office, underscores booming AI demand, electrifying investor confidence in AI-related stocks. The Productivity and Business Processes segment rose 10% to $29.9 billion, with AI-driven tools like Copilot boosting per-user revenue. Despite economic concerns, Microsoft’s stock climbed, signaling a potential rally for AI